FDA to Review Promising New Alzheimer’s Treatment on November 6, 2020
November 2, 2020 9:07 am Leave your thoughtsOn November 6, the Food and Drug Administration is convening a meeting of outside experts to review the data from two Phase 3 clinical trials of a new drug developed for treating cognitive and functional decline in early Alzheimer’s disease